Asthma
Conditions
Keywords
ipratropium bromide, methacholine PD20, tolerance
Brief summary
Study is looking at the development of tolerance to methacholine following regular use of ipratropium bromide in mild asthmatics.
Detailed description
This study is being conducted people with well controlled (mild) asthma to determine if ipratropium bromide taken three times daily for six days (i.e. 2 puffs in the morning, 2 puffs in the afternoon and 2 puffs in the evening) followed by a final dose on the morning of day 7 reduces the effectiveness of this medication on blocking the effect of methacholine challenge.
Interventions
DRUGIpratropium Metered Dose Inhaler
MDI to deliver 20mcg per puff ipratropium bromide
matched MDI to deliver inactive drug
Sponsors
University of Saskatchewan
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* airway responsiveness to methacholine * adequate baseline lung function * no respiratory infection or exposure to stimuli that may alter response to methacholine within 4 weeks
Exclusion criteria
* pregnancy * current smoker * requirement for medications other than salbutamol that will interfere with airway response to methacholine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Methacholine PD20 | Pre treatment | dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second) |
Countries
Canada
Outcome results
None listed